IGF-1 LR3 vs Pramlintide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

IGF-1 LR3

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.

Full details →

Pramlintide

Pramlintide (Symlin) is a synthetic analog of amylin, FDA-approved as an adjunct to insulin therapy in type 1 and type 2 diabetes. It helps control post-meal blood sugar spikes and promotes modest weight loss.

Full details →

Side-by-Side Comparison

AspectIGF-1 LR3Pramlintide
MechanismBinds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours.Mimics amylin's effects: slows gastric emptying, suppresses glucagon secretion after meals, and promotes satiety through central mechanisms. Complements insulin therapy.
Typical DosageResearch protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles.Type 1: Start 15mcg before meals, titrate to 30-60mcg. Type 2: Start 60mcg, may increase to 120mcg. Always with meal containing 30+ grams carbs or 250+ calories.
AdministrationIntramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off.Subcutaneous injection immediately before major meals. Must reduce mealtime insulin by 50% when starting to prevent hypoglycemia. Never mix with insulin.
Side EffectsHypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions.Nausea (very common initially), headache, anorexia, vomiting, and abdominal pain. GI effects typically improve over time.
Best For

What They Have in Common

Both IGF-1 LR3 and Pramlintide are commonly used for:

Key Differences

Ready to Learn More?